Comparison of Organic and Conventional Crops at the Neely-Kinyon Long-Term Agroecological Research (LTAR) Site, 2008

The Neely-Kinyon LTAR site was established in 1998 to study the long-term effects of organic production in Iowa. Treatments at the LTAR site, replicated four times in a completely randomized design, include the following rotations: conventional CornSoybean (C-S), organic Corn-SoybeanOats/Alfalfa (C-S-O/A), organic CornSoybean-Oats/Alfalfa-Alfalfa (C-S-O/A-A), and Soybean-Wheat (S-W). Arapahoe winter wheat was planted on October 30, 2007, at 85 lb/acre and Cardinal red clover was frostseeded into the wheat plots on March 12, 2008, at a rate of 15.5 lb/acre. On April 21, Kame oats were underseeded with Bluejay alfalfa at a rate of 93 lb/acre and 16 lb/acre, respectively. Following harvest of the organic corn plots in 2007, AC Remington winter rye was no-till drilled at a rate of 70 lb/acre on November 8, 2007

High Tunnel Bramble Production

High tunnels are polyethylene covered shelters being used in the vegetable industry to advance or extend the harvest season for many high value crops. Unlike traditional greenhouses, no supplemental heating is used in high tunnels. Brambles(raspberries and blackberries) are high value fruits that have good economic potential on small farms, but under Iowa conditions, they are not without risk. Traditionally, both crops are produced on biennial canes that grow vegetatively the first season (primocanes), and fruit in the second growing season (floricanes)

High Tunnel Bramble Production

In 2006, a study was initiated at the ISU Armstrong Research Farm (ARF) to evaluate the potential for growing high-value floricane and primocane type raspberries and blackberries in a high tunnel. The objectives were to determine if a high tunnel could be used to improve over-wintering of cold sensitive floricane types, and if the harvest season of primocane types could be advanced far enough ahead that they could replace the floricane types in such a production system. A second objective was to determine if these crops could be grown in a high tunnel without pesticides or minimum pesticide usage. This report summarizes the results for the 2009 through 2011growing seasons

High Tunnel Bramble Production

High tunnels are polyethylene covered shelters being used in the vegetable industry to advance or extend the harvest season for many high value crops. Unlike traditional greenhouses, no supplemental heating is used in high tunnels. In 2006, a study was initiated at the ISU Armstrong Research Farm (ARF) and the Horticulture Research Station (HRS) to evaluate the potential for growing highvalue floricane and primocane type raspberries and blackberries in a high tunnel. The objectives were to determine if a high tunnel could be used to improve over-wintering of cold sensitive floricane types, and if the harvest season of primocane types could be advanced enough that they could replace the floricane types in such a production system. A second objective was to determine if these crops could be grown in a high tunnel without pesticides or minimum pesticide usage. This report summarizes the results for the 2008 growing season

Caenorhabditis elegans Show Preference for Stimulants and Potential as a Model Organism for Medications Screening

The nematode Caenorhabditis elegans (C. elegans) is a popular invertebrate model organism to study neurobiological disease states. This is due in part to the intricate mapping of all neurons and synapses of the entire animal, the wide availability of mutant strains, and the genetic and molecular tools that can be used to manipulate the genome and gene expression. We have shown that, C. elegans develops a conditioned preference for cues that had previously been paired with either cocaine or methamphetamine exposure that is dependent on dopamine neurotransmission, similar to findings using place conditioning with rats and mice. In the current study, we show C. elegans also display a preference for, and self-exposure to, cocaine and nicotine. This substance of abuse (SOA) preference response can be selectively blocked by pretreatment with naltrexone and is consistent with the recent discovery of an opioid receptor system in C. elegans. In addition, pre-exposure to the smoking cessation treatment varenicline also inhibits self-exposure to nicotine. Exposure to concentrations of treatments that inhibit SOA preference/self-exposure did not induce any significant inhibition of locomotor activity or affect food or benzaldehyde chemotaxis. These data provide predictive validity for the development of high-throughput C. elegans behavioral medication screens. These screens could enable fast and accurate generation of data to identify compounds that may be effective in treating human addiction. The successful development and validation of such models would introduce powerful and novel tools in the search for new pharmacological treatments for substance use disorders, and provide a platform to study the mechanisms that underlie addictions

Instabilities in the wake of an inclined prolate spheroid

We investigate the instabilities, bifurcations and transition in the wake behind a 45-degree inclined 6:1 prolate spheroid, through a series of direct numerical simulations (DNS) over a wide range of Reynolds numbers (Re) from 10 to 3000. We provide a detailed picture of how the originally symmetric and steady laminar wake at low Re gradually looses its symmetry and turns unsteady as Re is gradually increased. Several fascinating flow features have first been revealed and subsequently analysed, e.g. an asymmetric time-averaged flow field, a surprisingly strong side force etc. As the wake partially becomes turbulent, we investigate a dominating coherent wake structure, namely a helical vortex tube, inside of which a helical symmetry alteration scenario was recovered in the intermediate wake, together with self-similarity in the far wake.Comment: Book chapter in "Computational Modeling of Bifurcations and Instabilities in Fluid Dynamics (A. Gelfgat ed.)", Springe

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council